Refinement in the treatment of invasive bladder cancer requires improved methods to predict the biologic behavior of tumors. Although DNA ploidy analysis represents an initial application of flow cytometry, it has proved to be a clinically useful test. Flow cytometric DNA ploidy analysis is compared to conventional prognostic indicators, and its current status in the management of patients with invasive bladder cancers is discussed.